David R. Healy
Pfizer (United States)(US)
Publications by Year
Research Areas
Bone health and treatments, interferon and immune responses, Bone health and osteoporosis research, Regulation of Appetite and Obesity, Parathyroid Disorders and Treatments
Most-Cited Works
- → A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing(2003)116 cited
- → Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice(2005)84 cited
- → Circulating Bone Morphogenetic Protein 1–3 Isoform Increases Renal Fibrosis(2011)62 cited
- → Surface-specific effects of a PPARγ agonist, darglitazone, on bone in mice(2006)55 cited
- → Short term immobilization-induced cancellous bone loss is limited to regions undergoing high turnover and/or modeling in mature rats(1997)48 cited
- → The discovery of novel calcium sensing receptor negative allosteric modulators(2009)41 cited
- → Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists(2009)25 cited
- → Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans(2009)22 cited
- Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats.(2004)
- → Metabolism-Guided Design of Short-Acting Calcium-Sensing Receptor Antagonists(2010)13 cited